Corpus Intelligence IC Memo — PETALUMA VALLEY HOSPITAL 2026-04-26 14:15 UTC
IC Memo — PETALUMA VALLEY HOSPITAL
Investment Committee Memorandum | CA | 58 beds | Grade D | EBITDA uplift $6.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PETALUMA VALLEY HOSPITAL

CCN 050136 | SONOMA, CA | 58 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

PETALUMA VALLEY HOSPITAL is a 58-bed community hospital in SONOMA, CA with $82.9M in net patient revenue and a -24.0% operating margin. The hospital serves a payer mix of 36.6% Medicare, 0.0% Medicaid, and 63.4% commercial.

Thesis: Turnaround. Our ML models identify $6.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -24.0% to -16.7% (+736bps).

Net Revenue HCRIS$82.9M
Current EBITDA COMPUTED$-19.9M
Operating Margin COMPUTED-24.0%
Occupancy HCRIS41.3%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS14.9%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
117
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -24.0% places it below the state median. Among 117 size-comparable peers (29-116 beds), the median margin is -5.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (29-116), prioritizing same-state peers. 117 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PETALUMA VALLEY HOSPITAL (Target)CA58$82.9M-24.0%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - FREMONTCA100$296.2M-6.6%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%
LLUMC MURRIETACA111$276.7M-20.3%
ADVENTIST HEALTH SONORACA84$274.3M-7.4%
CPMC-R.K. DAVIES MEDICAL CENTECA105$243.7M24.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.7M+210bp18mo
Cost to Collect4.5%2.5%$1.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.0M+122bp9mo
Clean Claim Rate88.0%96.0%$53K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.7M
Cost to Collect
$1.7M
Denial Rate Reduction
$1.6M
A/R Days Reduction
$1.0M
Clean Claim Rate
$53K
Total EBITDA Uplift$6.1M
Current EBITDA$-19.9M
+ RCM Uplift+$6.1M
Pro Forma EBITDA$-13.8M
Current Margin-24.0%
Pro Forma Margin-16.7%
WC Released (1x)$3.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-30.7M$-70.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-30.7M$-87.5M0.00x-100.0%
Bull Case9.0x11.0x$-27.6M$-77.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-27.6M$-92.5M0.00x-100.0%
Bear Case11.0x10.0x$-33.7M$-91.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-33.7M$-111.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 117 hospitals with 29-116 beds
  • Same-state prioritization (n=118)
  • Comp margins: P25=-20.7% / P50=-5.8% / P75=1.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.